期刊的影响因子--文章列表

期刊文章列表
Yinrong Wu，Zichao Yang，Kui Cheng，Huichang Bi，Jianjun Chen（Guangdong Provincial Key Laboratory of New Drug Screening，NMPA Key Laboratory for Research and Evaluation of Drug Metabolism，School of Pharmaceutical Sciences，Southern Medical University）.Small molecule-based immunomodulators for cancer therapy[J].Acta Pharmaceutica Sinica B,2022,第12期 Yanyan Xu¹，Jingyuan Xiong²，Xiyang Sun³，Huile Gao¹（Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry，Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology，West China School of Pharmacy，Sichuan University；Healthy Food Evaluation Research Center，West China School of Public Health and West China Fourth Hospital，Sichuan University；Hongqiao International Institute of Medicine，Tongren Hospital，School of Medicine，Shanghai Jiao Tong University）.Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第12期 Hao Ling¹，Xinyu Lou¹，Qiuhua Luo²，Zhonggui He¹，Mengchi Sun¹，Jin Sun¹（Wuya College of Innovation，Shenyang Pharmaceutical University；Department of Pharmacy，The First Affiliated Hospital of China Medical University）.Recent advances in bacteriophage-based therapeutics：Insight into the post-antibiotic era[J].Acta Pharmaceutica Sinica B,2022,第12期 Xiwei Ji¹，Xiangrui Meng²，Xiao Zhu³，Qingfeng He³，Yimin Cui¹（Institute of Clinical Pharmacology，Peking University First Hospital；Xiyuan Hospital，China Academy of Chinese Medical Sciences；Department of Clinical Pharmacy and Pharmacy Administration，School of Pharmacy，Fudan University）.Research and development of Chinese anti-COVID-19 drugs[J].Acta Pharmaceutica Sinica B,2022,第12期 Wan Li^1,2，Hongqing Cai^3,4，Liwen Ren^1,2，Yihui Yang^1,2，Hong Yang^1,2，Jinyi Liu^1,2，Sha Li^1,2，Yizhi Zhang^1,2，Xiangjin Zheng^1,2，Wei Tan^1,2,5,6，Guanhua Du^1,2，Jinhua Wang^1,2（The State Key Laboratory of Bioactive Substance and Function of Natural Medicines；Key Laboratory of Drug Target Research and Drug Screen，Institute of Materia Medica，Chinese Academy of Medical Science and Peking Union Medical College；Department of Neurosurgery，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College；State Key Laboratory of Molecular Oncology，Center for Cancer Precision Medicine，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College；School of Pharmacy，Xinjiang Medical University；Xinjiang Institute of Materia Medica）.Sphingosine kinase 1 promotes growth of glioblastoma by increasing inflammation mediated by the NF-κB/IL-6/STAT3 and JNK/PTX3 pathways[J].Acta Pharmaceutica Sinica B,2022,第12期 Minmin Fan^1,2，Jian Gao¹，Lin Zhou¹，Wenwen Xue¹，Yixuan Wang¹，Jingwei Chen¹，Wuhao Li¹，Ying Yu¹，Bo Liu³，Yan Shen¹，Qiang Xu¹（State Key Laboratory of Pharmaceutical Biotechnology，Nanjing Drum Tower Hospital，School of Life Sciences，Nanjing University；The First Clinical Medical College，Nanjing University of Chinese Medicine，Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor；State Key Laboratory of Biotherapy and Cancer Center，West China Hospital，Sichuan University，Collaborative Innovation Center of Biotherapy）.Highly expressed SERCA2 triggers tumor cell autophagy and is a druggable vulnerability in triple-negative breast cancer[J].Acta Pharmaceutica Sinica B,2022,第12期 Chuchu Lin¹，Chenyi Huang¹，Zhaoqing Shi²，Meitong Ou¹，Shengjie Sun¹，Mian Yu¹，Ting Chen²，Yunfei Yi¹，Xiaoyuan Ji^1,3，Feng Lv²，Meiying Wu¹，Lin Mei²（School of Pharmaceutical Sciences (Shenzhen)，Shenzhen Campus of Sun Yat-sen University；Tianjin Key Laboratory of Biomedical Materials，Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy，Institute of Biomedical Engineering，Chinese Academy of Medical Sciences and Peking Union Medical College；Academy of Medical Engineering and Translational Medicine，Medical College，Tianjin University）.Biodegradable calcium sulfide-based nanomodulators for H₂S-boosted Ca²⁺-involved synergistic cascade cancer therapy[J].Acta Pharmaceutica Sinica B,2022,第12期 Nannan Wang，Yueyue Zuo，Shengjie Wu，Chenlu Huang，Linhua Zhang，Dunwan Zhu（Tianjin Key Laboratory of Biomedical Materials，Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy，Institute of Biomedical Engineering，Chinese Academy of Medical Sciences ＆ Peking Union Medical College）.Spatio-temporal delivery of both intra- and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses[J].Acta Pharmaceutica Sinica B,2022,第12期 Kai Tang，Shu Wang，Wenshuo Gao，Yihui Song，Bin Yu（School of Pharmaceutical Sciences，Zhengzhou University）.Harnessing the cyclization strategy for new drug discovery[J].Acta Pharmaceutica Sinica B,2022,第12期 Dongrong Yi¹，Quanjie Li¹，Han Wang²，Kai Lv¹，Ling Ma¹，Yujia Wang¹，Jing Wang¹，Yongxin Zhang¹，Mingliang Liu¹，Xiaoyu Li¹，Jianxun Qi²，Yi Shi^2,3，George F.Gao^2,3，Shan Cen^1,4（Institute of Medicinal Biotechnology，Chinese Academy of Medical Sciences and Peking Union Medical School；CAS Key Laboratory of Pathogenic Microbiology and Immunology，Institute of Microbiology，Chinese Academy of Sciences；University of Chinese Academy of Sciences；CAMS Key Laboratory of Antiviral Drug Research，Institute of Medicinal Biotechnology，Peking Union Medical College，Chinese Academy of Medical Sciences）.Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein[J].Acta Pharmaceutica Sinica B,2022,第12期 Yuling Mao¹，Xiudan Wang¹，Caishun Chen¹，Qinfu Zhao¹，Yanfeng Liu²，Jinghai Zhang³，Siling Wang¹（Department of Pharmaceutics，School of Pharmacy，Shenyang Pharmaceutical University；School of Life Science and Bio-pharmaceutics，Shenyang Pharmaceutical University；Department of Biomedical Engineering，School of Medical Devices，Shenyang Pharmaceutical University）.Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors[J].Acta Pharmaceutica Sinica B,2022,第12期 Deying Yang¹，Xiang Luo¹，Qinghai Lian¹，Lingqiang Gao¹，Chengxin Wang¹，Xiaoxiao Qi¹，Rong Zhang¹，Zhongqiu Liu^1,2，Guochao Liao^1,2（Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People’s Republic of China，International Institute for Translational Chinese Medicine，Guangzhou University of Chinese Medicine；Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research）.Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development[J].Acta Pharmaceutica Sinica B,2022,第12期 Chengliang Sun^1,2，Yao Cheng^1,3，Xiaojia Liu⁴，Gefei Wang^1,2，Wenjian Min^1,2，Xiao Wang^1,2，Kai Yuan^1,2，Yi Hou^1,2，Jiaxing Li^1,2，Haolin Zhang^1,2，Haojie Dong^1,2，Liping Wang^1,2，Chenguang Lou⁵，Yanze Sun^1,2，Xinmiao Yu^1,2，Hongbin Deng⁶，Yibei Xiao^1,3，Peng Yang^1,2（State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization，China Pharmaceutical University；Department of Medicinal Chemistry，School of Pharmacy，China Pharmaceutical University；Department of Pharmacology，School of Pharmacy，China Pharmaceutical University；Beijing Institute of Clinical Pharmacy，Beijing Friendship Hospital，Capital Medical University；Department of Physics，Chemistry and Pharmacy，University of Southern Denmark；Institute of Medicinal Biotechnology，Chinese Academy of Medical Sciences & Peking Union Medical College）.Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents[J].Acta Pharmaceutica Sinica B,2022,第12期 Qiang Niu¹，Yu Liu²，Yujing Zheng²，Ziwei Tang¹，Yuna Qian^2,3，Ruogu Qi⁴，Jianliang Shen^2,3，Ping Zhao¹（School of Chemistry and Chemical Engineering，Guangdong Pharmaceutical University；State Key Laboratory of Ophthalmology，Optometry and Vision Science，School of Ophthalmology and Optometry，School of Biomedical Engineering，Wenzhou Medical University；Wenzhou Institute，University of Chinese Academy of Sciences；School of Medicine & Holistic Integrative Medicine，Nanjing University of Chinese Medicine）.Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics[J].Acta Pharmaceutica Sinica B,2022,第12期 Yan-Ping Wu^1,2,3,4，Rong-Rong He^1,2,3,4（Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility，Jinan University；School of Traditional Chinese Medicine，Jinan University；International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE)，College of Pharmacy，Jinan University；Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research，College of Pharmacy，Jinan University）.Commentary：Acute psychological stress redistributed leukocytes via distinct brain circuits[J].Acta Pharmaceutica Sinica B,2022,第12期 Yang Liu¹，Ning Zhang²，Cuicui Xie³，Yale Jiang¹，Yunhe Qin³，Liyun Zhou³，Yi Fan²，Lianjie Ren²，Chen Yin¹，Huan Yang²，Wei Xie³，Qing Zhai⁴，Guanqiao Li⁵，Hongzhuan Chen⁶，Xiaoyuan Chen^1,7（Tsinghua Clinical Research Institute (TCRI)，School of Medicine，Tsinghua University；Center for Drug Evaluation，National Medical Products Administration；Pharmcube (Beijing) Co.，Ltd.；Department of Clinical Pharmacy，Cancer Hospital of Fudan University；Vanke School of Public Health，Tsinghua University；Shanghai Collaborative Innovation Center for Translational Medicine，Shanghai University of Traditional Chinese Medicine；Office of Clinical Trial Institute，Beijing Tsinghua Changgung Hospital）.Evolution of drug regulations and regulatory innovation for anticancer drugs in China[J].Acta Pharmaceutica Sinica B,2022,第12期 Shujing Xu，Xinyong Liu，Peng Zhan（Department of Medicinal Chemistry，Key Laboratory of Chemical Biology，Ministry of Education，School of Pharmaceutical Sciences，Shandong University）.SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis[J].Acta Pharmaceutica Sinica B,2022,第12期 Yuyu Zhu¹，Zijun Ouyang²，Haojie Du³，Meijing Wang³，Jiaojiao Wang¹，Haiyan Sun²，Lingdong Kong³，Qiang Xu³，Hongyue Ma¹，Yang Sun^3,4（College of Pharmacy，Nanjing University of Chinese Medicine；Institute of Marine Biomedicine，School of Food and Drug，Shenzhen Polytechnic；State Key Laboratory of Pharmaceutical Biotechnology，School of Life Science，Nanjing University；Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy，Xuzhou Medical University）.New opportunities and challenges of natural products research：When target identification meets single-cell multiomics[J].Acta Pharmaceutica Sinica B,2022,第11期 Shilin Chen^1,2，Zheng Li³，Sanyin Zhang⁴，Yuxin Zhou^1,2，Xiaohe Xiao⁵，Pengdi Cui³，Binjie Xu⁴，Qinghe Zhao²，Shasha Kong²，Yuntao Dai²（Institute of Herbgenomics，Chengdu University of Traditional Chinese Medicine；Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences；State Key Laboratory of Component Traditional Chinese Medicine，College of Pharmaceutical Engineering of Traditional Chinese Medicine，Haihe Laboratory of Modern Chinese Medicine，Tianjin University of Traditional Chinese Medicine；Innovative Institute of Chinese Medicine and Pharmacy，Chengdu University of Traditional Chinese Medicine；China Military Institute of Chinese Medicine，Fifth Medical Center of Chinese PLA General Hospital）.Emerging biotechnology applications in natural product and synthetic pharmaceutical analyses[J].Acta Pharmaceutica Sinica B,2022,第11期 Xiaoyou Wang¹，Chong Li¹，Yiguang Wang²，Huabing Chen³，Xinxin Zhang⁴，Cong Luo⁵，Wenhu Zhou⁶，Lili Li⁷，Lesheng Teng⁸，Haijun Yu⁴，Jiancheng Wang²（College of Pharmaceutical Sciences，Southwest University；Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems，State Key Laboratory of Natural and Biomimetic Drugs，School of Pharmaceutical Sciences，Peking University；School of Radiation Medicine and Protection，Soochow University；Shanghai Institute of Materia Medica，Chinese Academy of Sciences；Department of Pharmaceutics，Wuya College of Innovation，Shenyang Pharmaceutical University；Xiangya School of Pharmaceutical Sciences，Central South University；CAS Center for Excellence in Nanoscience，CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety，National Center for Nanoscience and Technology；School of Life Sciences，Jilin University）.Smart drug delivery systems for precise cancer therapy[J].Acta Pharmaceutica Sinica B,2022,第11期 Saiyang Xie^1,2，Yun Xing^1,2，Wenke Shi^1,2，Min Zhang^1,2，Mengya Chen^1,2，Wenxi Fang^1,2，Shiqiang Liu^1,2，Tong Zhang^1,2，Xiaofeng Zeng³，Si Chen³，Shasha Wang³，Wei Deng^1,2，Qizhu Tang^1,2（Department of Cardiology，Renmin Hospital of Wuhan University；Hubei Key Laboratory of Metabolic and Chronic Diseases；Cardiovascular Research Institute of Wuhan University）.Cardiac fibroblast heat shock protein 47 aggravates cardiac fibrosis post myocardial ischemia-reperfusion injury by encouraging ubiquitin specific peptidase 10 dependent Smad4 deubiquitination[J].Acta Pharmaceutica Sinica B,2022,第11期 Liping Liao^1,2，Wenzhen Dang^3,1，Tingting Lin^1,2，Jinghua Yu¹，Tonghai Liu^1,2，Wen Li¹，Senhao Xiao^1,2，Lei Feng^1,2，Jing Huang^1,2，Rong Fu¹，Jiacheng Li^1,2，Liping Liu^1,2，Mingchen Wang^1,2，Hongru Tao¹，Hualiang Jiang^1,2，Kaixian Chen^1,2，Xingxing Diao¹，Bing Zhou^1,4，Xiaoyan Shen³，Cheng Luo^3,1,2,4,5（State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences；Department of Pharmacology & the Key Laboratory of Smart Drug Delivery，Ministry of Education，School of Pharmacy，Fudan University；School of Pharmaceutical Science and Technology，Hangzhou Institute for Advanced Study，University of Chinese Academy of Sciences；School of Pharmaceutical Sciences，Zhejiang Chinese Medical University）.A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1β and IL-6[J].Acta Pharmaceutica Sinica B,2022,第11期 Juan Pang^1,2，Jia Nuo Feng^2,3，Wenhua Ling¹，Tianru Jin^2,3,4（Department of Nutrition，School of Public Health，Sun Yat-sen Universitynstitute；Division of Advanced Diagnostics，Toronto General Hospital Research Ⅰ，University Health Network；Department of Physiology，Faculty of Medicine，University of Toronto；Banting and Best Diabetes Centre，Faculty of Medicine，University of Toronto）.The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs——Therapeutic potential exploration in lung injury[J].Acta Pharmaceutica Sinica B,2022,第11期 Jie Tu，Na Liu，Yahui Huang，Wanzhen Yang，Chunquan Sheng（School of Pharmacy，Second Military Medical University）.Small molecules for combating multidrug-resistant superbug Candida auris infections[J].Acta Pharmaceutica Sinica B,2022,第11期 Yan Li^1,2，Ya Chu^1,3，Guangjiang Shi^1,3，Xiaobin Wang¹，Wanli Ye^1,3，Chun Shan¹，Dajia Wang¹，Di Zhang³，Wei He³，Jingwei Jiang⁴，Shuqian Ma^1,3，Yuhong Han^1,3，Zhili Zhao¹，Shijia Du¹，Zhen Chen³，Zhiyu Li³，Yong Yang¹，Chen Wang²，Xi Xu³，Hongxi Wu³（Center for New Drug Safety Evaluation and Research，State Key Laboratory of Natural Medicines，China Pharmaceutical University；School of Life Science and Technology，China Pharmaceutical University；School of Pharmacy，China Pharmaceutical University；Jiangsu Key Lab of Drug Screening，China Pharmaceutical University）.A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer[J].Acta Pharmaceutica Sinica B,2022,第11期 Beifen Zhong¹，Jun Wan¹，Changhui Shang¹，Jiajia Wen²，Yujia Wang²，Jian Bai¹，Shan Cen²，Youcai Hu¹（State Key Laboratory of Bioactive Substance and Function of Natural Medicines，Institute of Materia Medica，Chinese Academy of Medical Sciences & Peking Union Medical College；Institute of Medicinal Biotechnology，Chinese Academy of Medical Sciences & Peking Union Medical College）.Biosynthesis of rumbrins and inspiration for discovery of HIV inhibitors[J].Acta Pharmaceutica Sinica B,2022,第11期 Zaigang Zhou^1,2，Jiashe Chen³，Yu Liu¹，Chunjuan Zheng⁴，Wenjuan Luo⁴，Lele Chen³，Shen Zhou³，Zhiming Li³，Jianliang Shen^1,2,5（State Key Laboratory of Ophthalmology，Optometry and Vision Science，School of Ophthalmology and Optometry，School of Biomedical Engineering，Wenzhou Medical University；Wenzhou Institute，University of Chinese Academy of Sciences；Department of the First Affiliated Hospital of Wenzhou Medical University；School & Hospital of Stomatology，Wenzhou Medical University；Oujiang Laboratory(Zhejiang Lab for Regenerative Medicine，Vision and Brain Health)）.Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第11期 Zekun Li¹，Yongchun Pan²，Shiyu Du¹，Yayao Li¹，Chao Chen¹，Hongxiu Song¹，Yueyao Wu¹，Xiaowei Luan²，Qin Xu²，Xiaoxiang Guan³，Yujun Song²，Xin Han¹（Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica，School of Medicine& Holistic Integrative Medicine，Jiangsu Joint International Research Laboratory of Chinese Medicine and Regenerative Medicine，Nanjing University of Chinese Medicine；College of Engineering and Applied Sciences，Jiangsu Key Laboratory of Artificial Functional Materials，State Key Laboratory of Analytical Chemistry for Life Science，Nanjing University；Department of Oncology，The First Affiliated Hospital of Nanjing Medical University）.Tumor-microenvironment activated duplex genome-editing nanoprodrug for sensitized near-infrared titania phototherapy[J].Acta Pharmaceutica Sinica B,2022,第11期 Chunying Liu¹，Shuangrong Ruan²，Ying He¹，Xuejing Li¹，Yuefei Zhu^1,3，Honglan Wang⁴，Hanwei Huang¹，Zhiqing Pang¹（School of Pharmacy，Fudan University，Key Laboratory of Smart Drug Delivery，Ministry of Education；The Institute for Biomedical Engineering & Nano Science，Tongji University School of Medicine；Department of Biomedical Engineering，Columbia University；Institute of Hematology，Union Hospital，Tongji Medical College，Huazhong University of Science & Technology）.Broad-spectrum and powerful neutralization of bacterial toxins by erythroliposomes with the help of macrophage uptake and degradation[J].Acta Pharmaceutica Sinica B,2022,第11期首页 1 2 3 4 5 下一页尾页共有11页，转到页

期刊文章列表